Related references
Note: Only part of the references are listed.Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease
A. J. Yarur et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Long-Term Outcome of Patients With Crohn's Disease Who Discontinued Infliximab Therapy Upon Clinical Remission
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
Henit Yanai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar et al.
GUT (2014)
Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study
Byron P. Vaughn et al.
INFLAMMATORY BOWEL DISEASES (2014)
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
R. Khanna et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
Fernando S. Velayos et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
